series-b
Stage
2017
Founded
5
Investors
About
Topas Therapeutics develops antigen-specific nanoparticle technology to induce immune tolerance for the treatment of autoimmune and immune-mediated diseases, with clinical programs including Phase 2 trials in celiac disease.
Explore Topas Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.